syndrome) and 5 were large rearrangements, adding up to >11 Mb per subject and comprising strong phenotype-related genes. One of those was a de novo complex rearrangement, and the remaining 4 duplications and 2 deletions were 130-900 kb in size, containing 1-7 genes, and were classified as variants of unknown clinical significance. Our study confirms aCGH as a powerful technique to ascertain the genetic etiology of fetal major congenital malformations.
features that are of no serious medical or cosmetic consequence to the patient'. They may be indicative of a more generalized altered morphogenesis or may represent a valuable indication for identifying a specific malformative syndrome [Jones et al., 2013; Kumar and Burton, 2007] .
Data from the EUROCAT network established a prevalence of MCMs in Europe of 2.6% between 2008 and 2012, including live births (2.1%) and fetal deaths/terminations of pregnancy after prenatal diagnosis (0.5%). Around 18% of MCMs were ascribed to known genetic conditions (http://www.eurocat-network.eu).
The genetic etiology of MCMs is widely variable: monogenic syndromes are estimated to account for 2-10% of cases, whereas chromosomal abnormalities are found in 10-15% of liveborns with MCMs [Stevenson and Hall, 2005] and in 9-39% of fetuses with abnormal ultrasound findings, depending on the presence of a single anomaly or multiple malformations [Wilson et al., 1992; Rizzo et al., 1996; Tseng et al., 2006; Yashwanth et al., 2010; Saldarriaga et al., 2015] . Subtelomeric deletions are present in ∼ 5% of patients with multiple CMs associated with mental retardation [Koolen et al., 2004] . Retrospective studies using array-comparative genomic hybridization (aCGH) in fetuses with multiple malformations report a detection rate of pathogenic chromosomal imbalances from 8-18% and a 10% increase in the diagnostic yield of chromosomal microarray over karyotyping (95% confidence interval) [Schaeffer et al., 2004; Le Caignec et al., 2005; Tyreman et al., 2009; Vialard et al., 2009; Hillman et al., 2013; de Wit et al., 2014] . It is estimated that ∼ 50% of CMs have an unknown etiology [Rajangam and Nanjappa, 2007] .
In this work, we evaluated the detection rate of aCGH analysis in identifying pathogenic chromosomal deletions/duplication in a group of fetuses with single or multiple CMs.
Materials and Methods

Cases and Anatomopathological Evaluation
Between January 2010 and September 2013, ∼ 960 fetuses underwent autopsy following spontaneous abortions, intrauterine/ neonatal deaths, and termination of pregnancy for fetal anomalies at the Città della Salute e della Scienza di Torino, University Hospital. Fetal autopsy included evaluation of the external appearance, measurement of morphometric parameters, examination of thorax and abdominal anatomy, and histological examination of main organs and pathological tissues. Skeletal X-ray analysis was performed on each fetus. Fetuses with suspicious infective causes of anomalies were excluded by placental examination. Excluding cases suggestive of a monogenic disease or a non-genetic origin, we selected 49 fetuses with MCMs. Sixteen aCGH analyses failed due to inadequate quality of the genomic DNA. The remaining 33 analyses were performed on 9 fetuses with 1 MCM and 24 with 2 or more MCMs.
Karyotyping and aCGH Analysis
Karyotyping on GTG-banded chromosomes ( ≥ 400 bands) was performed on chorionic villus sampling, amniotic fluid, or fibroblasts. Genomic DNA was extracted from fetal frozen tissues using the DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. aCGH was performed using a 60K whole-genome oligonucleotide microarray following the manufacturer's protocol (Agilent Technologies, Santa Clara, Calif., USA). Slides were scanned using a G2565BA scanner and analyzed using Agilent CGH Analytics software ver. 4.0.81 (Agilent Technologies) with the statistical algorithm ADM-2 and a sensitivity threshold of 6.0. Significant copy number changes were identified by at least 3 consecutive aberrant probes. Reference human genomic DNA was GRCh37/hg19. We followed pathogenicity criteria for CNVs as reported in Kearney et al. [2011] .
Sequencing Analysis
In patient 3 (DGT300197), we detected 2 SNPs in the 5 ′ -UTR (rs139428292: G>A) and in the first intron (rs201779890: G>C) of the RBM8A (RNA binding motif protein 8A) gene by Sanger sequencing. The PCR conditions were: 10 μ M primers (5 ′ -gcctttgattggtcagcttg; 5 ′ -aagggggcggaatctctaat), 200 μ M dNTPs, 60 ng of genomic DNA, and 0.5 U of KAPA-fast 2G kit (Kapa Biosystems, Inc., Mass., USA) in a 25-μl final volume under standard amplification conditions (56 ° C annealing temperature). PCR products were purified using Agencourt AMPure XP-PCR Purification (Beckman Coulter, Miami, Fla., USA) and sequenced with the Big Dye v3.1 kit (Applied Biosystems, Foster City, Calif., USA). Products were purified using Agencourt CleanSEQ-Dye Terminator Removal (Beckman Coulter) and run on an ABI-3730 platform using the POP7 polymer (Applied Biosystems).
Results
Standard karyotype analysis was negative on fetal tissue samples, with the exception of 9 samples in which the analysis was not possible due to culture failure. Using aCGH, we identified 1 or more copy number variants (CNVs) in 14 cases (14/33, 42%). Eight cases were classified as pathogenic which accounts for a detection rate of 24% (8/33) considering fetuses with 1 or more CMs and 33% (8/24) taking in account fetuses with multiple malformations only. Among the 8 pathogenic variants, 3 were associated with known microdeletion syndromes: a chromosome 22q11.21 deletion syndrome (MIM 188400), a central chromosome 22q11.21 deletion syndrome [Rump et al., 2014] , and a thrombocytopenia absent-radius (TAR) syndrome (MIM 274000; table 1 , cases 1-3). The majority of TAR patients are compound heterozy- gous for a deletion of 1q21.1 encompassing the RBM8A gene and a low-functioning SNP in either its 5 ′ -UTR or intron 1 [Albers et al., 2012] . By sequencing analysis in our TAR case, we identified one of those variants, the hypomorphic 'C' allele of SNP rs#201779890 in intron 1 of the non-deleted allele.
In the other 5 pathogenic CNVs, the extension of the total rearrangements per subject (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , and the number and the type of genes involved allowed the clear classification of the CNV as pathogenic ( table 1 , cases 4-8).
Cases 4 and 5 are already detailed in Di Gregorio et al. [2014] as examples of cryptic large CNVs (>6 Mb) undetectable by conventional karyotyping.
Briefly, fetus 4 showed a complex phenotype, displaying partially overlapping features with Cornelia de Lange syndrome (MIM 122470). We found 2 large telomeric rearrangements: a 3q27.1q29 duplication (13.4 Mb) associated with the Cornelia de Lange phenotype [Holder et al., 1994; Dundar et al., 2011 ] and a 15q26.1q26.3 deletion (11.5 Mb) encompassing the minimal region of the 15q26qter deletion syndrome (MIM 612626).
Case 5 carried 2 duplications on chromosome 7p22.3p22.2 and 7p22.1p21.2 and a deletion of chromosome 11q24.1q25. The duplication of the short arm of chromosome 7 causes a characteristic pattern of malformations including developmental, craniofacial, skeletal, and cardiovascular anomalies, the severity of which depends on the size of the duplication [Papadopoulou et al., 2006] . The neuronal migration defect could be explained by the deletion of CDON (cell adhesion molecule-related/ downregulated by oncogenes, MIM 608707) and KIRREL3 (Kin of IRRE-like 3, MIM 607761) on chromosome 11, which are 2 genes involved in the control of neuronal migration and axon guidance [Okada et al., 2006; Bhalla et al., 2008] . The cardiac phenotype (hypoplastic left heart) is likely to be part of the Jacobsen syndrome spectrum (MIM 147791) due to the 11q24.1-11qter deletion [Grossfeld et al., 2009] .
In case 6, we found 6 de novo duplications ranging from 37 kb to 4.8 Mb, with a total of 15.5 Mb, involving 6 different chromosomes. Among these, the 2q31.1 duplication spanned the HOXD gene cluster, a family of highly conserved transcription factors involved in the anterior-posterior development of the limb and in the specification of the fingers [Kessel and Gruss, 1990; Johnson et al., 1998; Johnson et al., 2003] , and could explain the polydactyly and digital shape anomalies in the fetus. Overexpression of HOXD10 in mice causes polydactyly, whereas the duplication of the HOXD gene cluster modifies finger-shape and -number in mice [Zakany et al., 2004; Tarchini et al., 2006; Sheth et al., 2007] . The other 5 identified rearrangements could not be clearly related to the remaining clinical features. Moreover, aCGH analysis of the parents showed a 1.8-Mb duplication of chromosome 2q12.3q13 in the father.
Case 7 carried a large 13.5-Mb deletion of chromosome 15q25.3q26.3, partially overlapping with the 15q26qter deletion syndrome region (MIM 612626) . This fetus and patients carrying a 15q26qter deletion show micrognathia, which is part of the Pierre-Robin sequence [Roback et al., 1991; Tonnies et al., 2001] . Furthermore, the same region is associated with diaphragmatic hernia, also present in our case (MIM 142340) [Castiglia et al., 2005; Klaassens et al., 2005 Klaassens et al., , 2007 Mosca et al., 2011] . IGF1R and ARRDC4 have been identified as the strongest candidate genes for this phenotype, because both are expressed in the developing diaphragm. Nasal bone agenesis could be explained by genes in the centromeric segment non-overlapping the 15q26qter deletion.
Case 8 showed a 11.4-Mb deletion of chromosome 3p14.2p13. One of his key features was the presence of a congenital heart defect (CHD; table 1 ). Assessing the pathogenicity of a CNV associated with CHD is not always straightforward as many deletions/duplications encompass genes that are not clearly related to cardiac development [Richards and Garg, 2010] . A notable gene present in the deleted region was FOXP1 (Forkhead Box P1, MIM 605515), which is critical for heart development and was also found to be deleted in a patient with an atrioventricular septal defect [Chang et al., 2013] . Moreover, a rare contiguous gene syndrome has been described in patients carrying a chromosome 3p14 deletion; key features of this syndrome include short stature, dysmorphisms, CHD, developmental delay, and urogenital and neurological problems [Dimitrov et al., 2015] . Interestingly, scrotal hypoplasia in the fetus might be explained by the deletion of the PROK2 gene (Prokineticin 2 , MIM 607002). Point mutations in this gene cause Kallmann syndrome type 4 [Dode et al., 2006] , a disease featuring hypogonadotropic hypogonadism with testicular/scrotal atrophy (MIM 610628). A second candidate gene was the testis-expressed GPR27 (G-protein-coupled receptor 27, MIM 605187), whose function is still poorly defined. Clenched hands in the fetus could be explained by the deletion of FOXP1 as hypothesized in a patient with limb contractures, speech delay, hypertonia, and blepharophimosis carrying a 785-kb de novo 3p14 deletion: FOXP1 haploinsufficiency may be involved in defects of motor neuron development resulting in limb contractures [Pariani et al., 2009] .
Among the analyzed fetuses, 6/33 (18%) carried CNVs ranging from 130-900 kb (4 duplications and 2 deletions), classified as variants of unknown clinical significance (VOUS), which contained 1-7 genes. Segregation of the identified variants could not be assessed. In these regions, no obvious candidate genes could be associated with clinical features of the fetuses.
Discussion
In the recent years, about 20 studies have examined the potential impact/pathogenicity of CNVs in fetal malformations in a prenatal diagnostic setting or after terminations of pregnancy [de Wit et al., 2014; Papoulidis et al., 2015; Srebniak et al., 2015] . The proportion of clinically relevant findings is highly variable (from 4.3 to 18%) [de Wit et al., 2014; Papoulidis et al., 2015; Srebniak et al., 2015] , reaching 24% with our study. Discrepancies among studies may be due to different technical platforms, different selection criteria, the size of the sample, or the inclusion of VOUS among the identified CNVs. Based on the reported data, selection criteria are particular relevant: among our 24 cases with multisystem anomalies (2-4 organ systems), we found 14 cases with a positive aCGH result (54%), and 8 of these had true pathogenic variants (33%).
Notably, 4 of the 8 cases carried at least 1 rearrangement >10 Mb which was undetected by conventional chromosomal analysis. This may be due to the low karyotype resolution on chorionic villi or fetal fibroblasts or to cryptic rearrangements as described by Di Gregorio et al. [2014] . Indeed, in a recent meta-analysis such large anomalies were excluded from the reported results, lowering the percentage of aCGH detection [de Wit et al., 2014] . Using these criteria, we would estimate a rate of 15% of pathogenic CNVs detected by aCGH, in-line with published data.
We classified all the rearrangements without obvious biological effect, absent in the DGV database, and/or those for which it was not possible to perform segregation analysis as VOUS. Our results showed a higher percentage of VOUS in comparison to reported studies, where the detection rate ranged from 0.5 to 1.7% [Brady et al., 2014; Papoulidis et al., 2015] . This discrepancy may be due to (a) VOUS definition, considering that some groups do not report rearrangements containing no genes [Brady et al., 2014] ; (b) array resolution (e.g. BAC array vs. oligonucleotide-array); (c) lack of knowledge about de novo versus inherited VOUS, which are often considered benign if inherited from an healthy parent, especially if gene-devoid, and (d) the presence of pathogenic CNVs among VOUS. Two of the detected VOUS were >500 kb, above an indicative limit of pathogenicity of 400 kb [Miller et al., 2010] , and one contained 7 genes.
Genetic counseling to couples after termination of pregnancy due to a fetal malformation is particularly difficult. Phenotypic diagnosis is often impossible, and karyotype analysis has a limited detection rate. aCGH data in our report demonstrate that the presence of pathogenic CNVs can allow a more precise evaluation of the recurrence risk. This was particularly important for cases in which the derivative of a cryptic rearrangement present in one of the parents was identified (cases 4 and 5) or for the known 22q11.21 and TAR syndromes (cases 1, 2, and 3), which are associated with a significant recurrence risk, giving the possibility of an early prenatal test in subsequent pregnancies.
aCGH using genomic DNA allows to overcome tissue culture difficulties and the low resolution of prenatal/fetal karyotypes. Furthermore, balanced rearrangements undetectable with aCGH (e.g. translocations/insertions) are very unlikely causes of fetal malformations, suggesting this method to be suitable as a first-tier analysis [Astbury et al., 2004] . However, given the high cost of the technique, PCR-based rapid aneuploidy detection should be recommended before aCGH.
In conclusion, we confirm aCGH as a powerful technique to identify pathogenic chromosomal rearrangements in fetuses with MCMs, with a higher detection rate proportional to the severity of the MCMs.
